GLOD5 | Glyoxalase domain containing 5 | | | | | | Tissue enhanced |
GNG13 | Guanine nucleotide binding protein (G protein), gamma 13 | RAS pathway related proteins
| | | | | Tissue enhanced |
GPR128 | G protein-coupled receptor 128 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GPR35 | G protein-coupled receptor 35 | G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
HAPLN4 | Hyaluronan and proteoglycan link protein 4 | Predicted secreted proteins
| | | | | Tissue enhanced |
HEPACAM2 | HEPACAM family member 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
HKDC1 | Hexokinase domain containing 1 | Enzymes
| | | | | Tissue enhanced |
HNF1A | HNF1 homeobox A | Cancer-related genes Disease related genes Transcription factors
| | | | | Tissue enhanced |
HNF4A | Hepatocyte nuclear factor 4, alpha | Disease related genes Nuclear receptors Transcription factors
| | | | | Tissue enhanced |
HNF4G | Hepatocyte nuclear factor 4, gamma | Nuclear receptors Transcription factors
| | | | | Tissue enhanced |
HRASLS2 | HRAS-like suppressor 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
HTR4 | 5-hydroxytryptamine (serotonin) receptor 4, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
KCNH6 | Potassium voltage-gated channel, subfamily H (eag-related), member 6 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KIAA1658 | | | | | | | Tissue enhanced |
LGALS4 | Lectin, galactoside-binding, soluble, 4 | Cancer-related genes Plasma proteins
| | | | | Tissue enhanced |
LRAT | Lecithin retinol acyltransferase (phosphatidylcholine--retinol O-acyltransferase) | Disease related genes Enzymes Potential drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LRRC19 | Leucine rich repeat containing 19 | Predicted membrane proteins
| | | | | Tissue enhanced |
LRRC66 | Leucine rich repeat containing 66 | Predicted membrane proteins
| | | | | Tissue enhanced |
MARVELD3 | MARVEL domain containing 3 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
MIA2 | Melanoma inhibitory activity 2 | Predicted secreted proteins
| | | | | Tissue enhanced |
MISP | Mitotic spindle positioning | Cytoskeleton related proteins
| | | | | Tissue enhanced |
MME | Membrane metallo-endopeptidase | Cancer-related genes Candidate cardiovascular disease genes CD markers Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
MNX1 | Motor neuron and pancreas homeobox 1 | Cancer-related genes Disease related genes Plasma proteins Transcription factors
| | | | | Tissue enhanced |
MOGAT3 | Monoacylglycerol O-acyltransferase 3 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
MT1H | Metallothionein 1H | | | | | | Tissue enhanced |
MT1HL1 | Metallothionein 1H-like 1 | | | | | | Tissue enhanced |
MYO7B | Myosin VIIB | Cytoskeleton related proteins
| | | | | Tissue enhanced |
NAALADL1 | N-acetylated alpha-linked acidic dipeptidase-like 1 | Enzymes Plasma proteins
| | | | | Tissue enhanced |
NAGS | N-acetylglutamate synthase | Disease related genes Enzymes Mitochondrial proteins Potential drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
NR1H4 | Nuclear receptor subfamily 1, group H, member 4 | Nuclear receptors Transcription factors
| | | | | Tissue enhanced |
OLFM4 | Olfactomedin 4 | Predicted secreted proteins
| | | | | Tissue enhanced |
OMP | Olfactory marker protein | | | | | | Tissue enhanced |
P2RY4 | Pyrimidinergic receptor P2Y, G-protein coupled, 4 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
PDZD3 | PDZ domain containing 3 | | | | | | Tissue enhanced |
PDZD7 | PDZ domain containing 7 | Disease related genes
| | | | | Tissue enhanced |
PHGR1 | Proline/histidine/glycine-rich 1 | | | | | | Tissue enhanced |
PLA2G2A | Phospholipase A2, group IIA (platelets, synovial fluid) | Enzymes FDA approved drug targets Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
PLB1 | Phospholipase B1 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
PLEKHG6 | Pleckstrin homology domain containing, family G (with RhoGef domain) member 6 | | | | | | Tissue enhanced |
PLEKHS1 | Pleckstrin homology domain containing, family S member 1 | | | | | | Tissue enhanced |
PLS1 | Plastin 1 | | | | | | Tissue enhanced |
PRKG2 | Protein kinase, cGMP-dependent, type II | Enzymes
| | | | | Tissue enhanced |
PRODH | Proline dehydrogenase (oxidase) 1 | Disease related genes Enzymes Mitochondrial proteins Potential drug targets
| | | | | Tissue enhanced |
PRR15 | Proline rich 15 | | | | | | Tissue enhanced |
PTPRH | Protein tyrosine phosphatase, receptor type, H | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
REEP6 | Receptor accessory protein 6 | Predicted membrane proteins
| | | | | Tissue enhanced |
REG1B | Regenerating islet-derived 1 beta | Predicted secreted proteins
| | | | | Tissue enhanced |
RNF186 | Ring finger protein 186 | Predicted membrane proteins
| | | | | Tissue enhanced |
RP11-1220K2.2 | Putative inactive maltase-glucoamylase-like protein LOC93432 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
RP11-187E13.1 | Uncharacterized protein | | | | | | Tissue enhanced |